Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75473
UPID:
LGR5_HUMAN
Alternative names:
G-protein coupled receptor 49; G-protein coupled receptor 67; G-protein coupled receptor HG38
Alternative UPACC:
O75473; D8MCT0; Q4VAM0; Q4VAM2; Q9UP75
Background:
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) serves as a receptor for R-spondins, enhancing the canonical Wnt signaling pathway. It is a pivotal stem cell marker in the intestinal epithelium and hair follicle. LGR5 facilitates the association with phosphorylated LRP6 and frizzled receptors activated by Wnt, augmenting gene expression. Unlike typical G-protein coupled receptors, LGR5 does not engage heterotrimeric G-proteins for signal transduction.
Therapeutic significance:
Understanding the role of Leucine-rich repeat-containing G-protein coupled receptor 5 could open doors to potential therapeutic strategies.